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levels were confirmed in murine NASH liver samples.  Our 
results suggest increased bile acid synthesis in NASH sam-
ples, as judged by the enhanced level of 7-hydroxycholest-4-
en-3-one and impaired 24S-hydroxycholesterol metabolism 
as characteristic biochemical changes in livers affected by 
NASH.—Raselli, T., T. Hearn, A. Wyss, K. Atrott, A. Peter, I. Frey-
Wagner, M. R. Spalinger, E. M. Maggio, A. W. Sailer, J. Schmitt, 
P. Schreiner, A. Moncsek, J. Mertens, M. Scharl, W. J. Griffiths, 
M. Bueter, A. Geier, G. Rogler, Y. Wang, and B. Misselwitz. Ele-
vated oxysterol levels in human and mouse livers reflect non-
alcoholic steatohepatitis. J. Lipid Res. 2019. 60: 1270–1283.
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Nonalcoholic fatty liver disease (NAFLD) is the most fre-
quent liver disease in industrialized countries (1). The 
prevalence of NAFLD ranges from 11% to 46%, with a 
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continuous increase in incidence within the last two de-
cades (2–7). NAFLD reflects liver injury in the setting of 
overnutrition, sedentary life style, obesity, and metabolic syn-
drome. NAFLD comprises a clinical spectrum ranging from 
benign liver steatosis to nonalcoholic steatohepatitis (NASH), 
with its associated complications liver fibrosis, liver cirrho-
sis, and hepatocellular carcinoma. Because therapeutic op-
tions for viral hepatitis have improved dramatically, NASH 
is expected to be the main cause of chronic liver disease in 
the years to come (5). Despite a large number of ongoing 
clinical trials, no medical treatment for NASH has been es-
tablished to date (8, 9).
The pathogenesis of NASH is still incompletely understood; 
current concepts implicate lipids and toxic lipid metabo-
lites, reactive oxygen species, or products of the intestinal 
microbiota as causes of liver injury, which would lead to 
liver infiltration by immune cells and continued destruction 
of liver tissue (10–12). However, the pathway from tissue 
metabolic derangement to liver inflammation and fibrosis 
is complex and not yet sufficiently clarified.
Oxysterols are oxidized cholesterol molecules that are 
formed in the early steps of cholesterol metabolism and 
bile acid synthesis. They are regulators of lipid metabolism 
with important metabolic functions, including the induction 
of key enzymes of the bile acid pathway, stimulation of reverse 
cholesterol transport, and regulation of hepatic cholesterol 
and fatty acid synthesis (13). Importantly, metabolic changes 
in NAFLD patients are accompanied by increased serum 
concentrations of oxysterols such as 25-hydroxycholesterol 
(25-HC) and 27-hydroxycholesterol [27-HC; synonym: 
(25R)26-hydroxycholesterol] (14). However, the full ex-
tent of changes in oxysterol metabolism in liver tissue over 
the spectrum of disease from bland steatosis to NASH and 
fibrosis has been insufficiently studied.
It is currently unclear whether oxysterols are active play-
ers or bystanders in NASH pathogenesis, but some argu-
ments for an active role have been put forward: In a 
murine model of NASH, the inhibition of 27-HC synthesis 
(due to knockdown of the enzyme CYP27A1) resulted in 
stronger NASH activity compared with wild-type and sub-
cutaneous application of 27-HC, which substantially de-
creased liver inflammation (15). The protective effects of 
oxysterols are not limited to 27-HC; in animal models of 
obesity or diabetes mellitus, the enzyme CYP7B1 (mediat-
ing 7-hydroxylation of oxysterols) is dramatically down-
regulated (16–18). In line with these observations, the 
transient hepatic overexpression of CYP7B1 in obese mice 
improved hepatic steatosis and metabolic syndrome (16).
Oxysterols have also been implicated as critical immune 
regulatory molecules (19–21). 25-HC is part of the rapid 
innate immune response and can induce macrophage ac-
tivation (19, 22, 23), T-cell differentiation (20), and the pro-
duction of IL-8 (24–26) and IL-6 (23). It has also been shown 
to have strong antiviral activity against many enveloped vi-
ruses (21, 27, 28). Furthermore, 25-HC has been shown to 
inhibit the activation of the DNA sensor protein AIM2, pre-
venting spurious AIM2 inflammasome activation (29).
The oxysterol 7,25-dihydroxycholesterol (7,25-diHC) 
was discovered as a ligand for the Epstein-Barr virus-induced 
G protein-coupled receptor 2 (EBI2; also known as GPR183) 
(30, 31). 7,25-diHC is produced by 25-hydroxylation of 
cholesterol by CH25H followed by 7-hydroxylation by 
CYP7B1 (32). The EBI2-7,25-diHC system can stimulate the 
migration of B-, T-, and dendritic cells and is crucial for an early 
antibody response against T-cell-dependent antigens (33). 
EBI2-dependent immune cell migration is a fundamental im-
munological mechanism in diverse processes, including IgG 
production (30), asthma (34) and encephalitis (35, 36).
EBI2 is also involved in intestinal inflammation: EBI2 
was described as an inflammatory bowel disease risk gene 
(37), and recent data demonstrate a role of EBI2 in the 
induction of colitis (38, 39). EBI2 and its oxysterol ligands 
thereby promote the development of lymphoid structures 
in the large intestine in health and accumulation of lym-
phoid tissue in inflammation, potentially facilitating an in-
flux of immune cells into the gut.
Taken together, oxysterols have regulatory effects for fat 
and cholesterol metabolism as well as the immune system, 
rendering these molecules interesting candidates as key 
mediators of NASH pathogenesis. We therefore set out to 
analyze free oxysterol levels in human NASH and per-
formed a systematic study using a physiological murine 
feeding model and knockout mice of key players of the 
EBI2 and 7,25-diHC axis to rigorously assess a role of 
EBI2 and its ligand in the pathogenesis of NASH.
MATERIALS AND METHODS
Patients
Bariatric patients were included in the study when the following 
inclusion criteria were met: age 18 years; BMI >35 kg/m2; and 
failed attempt for weight reduction 2 years or 1 year if BMI 
>50 kg/m2. Exclusion criteria were pregnancy, inflammatory bowel 
disease, liver cirrhosis Child B/C, or the presence of another seri-
ous medical, surgical, or psychiatric condition precluding bariatric 
surgery. All patients provided written informed consent prior to 
being included in this study. The study was performed according 
to the principles of the Helsinki Declaration and approved by the 
ethics committee of Zurich County (KEK-ZH-Nr. 2012-0260).
Baseline characteristics were collected the day of bariatric sur-
gery (Roux-en-Y gastric bypass or gastric sleeve surgery). A liver 
biopsy was acquired intraoperatively using a 18 G Tru-Cut biopsy 
needle that yielded 4–16 mg liver tissue, which was immediately 
frozen in liquid nitrogen. Four biopsy specimens were obtained 
from the resected specimen of liver resections with informed con-
sent and ethics approval (KEK-ZH-no. 2013-0503).
Animals
The animal experimental protocol was approved by the local 
animal welfare authority (Tierschutzkommision Zürich, Zurich, 
Switzerland; registration number ZH 50/2013).
CH25H-deficient mice (Ch25h/) in a C57BL/6 background 
and EBI2-deficient mice (Ebi2/) in a C57BL/6 background were 
provided by Novartis Institutes for BioMedical Research (40, 41). 
CYP7B1-deficient mice (Cyp7b1/) were purchased from Jackson 
Laboratories. All mice were bred in our animal facility with pure 
C57BL/6 mice to generate heterozygous mice (Ch25h+/, Ebi2+/, 
or Cyp7b1+/). Heterozygous mice were subsequently crossed with 
each other to obtain wild-type (Ch25h+/+, Ebi2+/+, or Cyp7b1+/+) and 
knockout (Ch25h/, Ebi2/, or Cyp7b1/) littermates. The 
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mice were housed under specific pathogen-free conditions in 
individually ventilated cages. Eight-week-old male littermates were 
used for all studies. NAFLD was induced by ad libitum feeding of 
a high-fat, high-cholesterol diet (ssniff Spezialdiäten GmbH) and 
high-fructose corn-syrup equivalent (55% fructose and 45% glu-
cose) (42) in drinking water at a concentration of 42 g/l for either 
10 or 20 weeks. Control mice received standard laboratory chow 
(Provimi Kliba) and water ad libitum.
Sterol extraction, derivatization, and LC-MS
The method for sterol extraction, derivatization, and LC-MS has 
been previously described in detail (43). The sterols measured 
here are free nonesterified cholesterol and oxysterols, which are 
different from total sterols, that is, the sum of esterified and non-
esterified molecules referred to below. We opted for measuring 
free oxysterols because free oxysterols better reflect the biological 
activity. Briefly, liver tissue was homogenized in ethanol contain-
ing deuterated internal standards; oxysterols were separated from 
cholesterol by C18 solid-phase extraction and derivatized with 
Girard P reagent (US Biological) with or without prior oxidation 
of 3-hydroxy to 3-oxo groups. The oxysterols were analyzed using 
LC-MSn (multistage fragmentation) on an Orbitrap Elite mass 
spectrometer.
The following oxysterols were quantified: 7-hydroxycholesterol 
(7-HC, cholest-5-ene-3,7-diol); 7-hydroxycholest-4-en-3-one 
(7-HCO); 22R-hydroxycholesterol (22R-HC, cholest-5-en-3,22R-
diol), 27-HC (cholest-5-ene-3,(25R)26-diol); 25-HC (cholest-5-ene-
3,25-diol); 24S-hydroxycholesterol (24S-HC, cholest-5-ene-3,24S-
diol); 24R-hydroxycholesterol (24R-HC, cholest-5-ene-3,24R-
diol); 7-hydroxycholesterol (7-HC, cholest-5-ene-3,7-diol); 
6-hydroxycholesterol (6-HC, cholest-5-ene-3,6-diol); 7,12-
dihydroxycholesterol (7,12-diHC, cholest-5-ene-3,7,12-triol); 
7,12-dihydoxycholest-4-en-3-one (7,12-diHCO); 7,27-
dihydroxycholesterol (7,27-diHC, cholest-5-ene-3,7,(25R)26-
triol); 7,27-dihydroxycholest-4-en-3-one (7,27-diHCO; 7,(25R)26-
dihydroxycholest-4-en-3-one); 7,25-diHC (cholest-5-ene-3,7,25-
triol); 20R,22R-dihydroxycholesterol (20R,22R-diHC, cholest-5- 
ene-3,20R,22R-triol); and 7,24S-dihydroxycholesterol (7,24S-
diHC, cholest-5-ene-3,7,24S-triol) in addition to cholesterol and 
3-hydroxycholest-5-en-(25R)26-oic acid.
As standards for measurements, 7,12-dihydroxycholest-4-
en-3-one was purchased from Toronto Research Chemicals. 
20R,22R-diHC was a gift from Ingemar Björkhem (Karolinska 
Institute). All other oxysterol standards were purchased from 
Avanti Polar Lipids.
Measurement of biochemical parameters in patient serum
Aspartate transaminase (AST), alanine transaminase (ALT), 
and total cholesterol (sum of cholesterol esters and free choles-
terol) were measured using Fuji Dri-Chem slides (Fujifilm) on a 
Dri-Chem NX500 device (Fujifilm).
RNA isolation, cDNA synthesis, and real-time PCR
Total RNA was isolated using the RNeasy Plus Mini Kit 
(QIAGEN). Lysis buffer from the kit was added to snap-frozen re-
sections, and samples were shredded in M tubes (Miltenyi Biotec) 
in a gentleMACS tissue homogenizer (Miltenyi Biotec). Total 
RNA was prepared according to the manufacturer’s instructions. 
On-column DNase digestion with RDD buffer (QIAGEN) was per-
formed for 15 min at room temperature. RNA concentration was 
determined by absorbance at 260 and 280 nm. cDNA (cDNA) syn-
thesis was performed using a high-capacity cDNA reverse-tran-
scription kit (Applied Biosystems) following the manufacturer’s 
instructions. Real-time PCR was performed using the TaqMan 
Fast Universal Master Mix (Applied Biosystems) on a Fast 7900HT 
real-time PCR system and the SDS software (Applied Biosystems). 
The real-time PCR started with an initial enzyme activation step 
(5 min; 95°C), followed by 45 cycles consisting of a denaturing 
(95°C; 15 s) and annealing/extending (60°C; 1 min) step. For each 
sample, triplicates were measured, and hypoxanthine-guanine 
phosphoribosyltransferase was used as endogenous control. Results 
were analyzed by the CT method. All gene expression assays 
were obtained from Life Technologies.
Histology
Livers were fixed in 4% paraformaldehyde and embedded in 
paraffin. Histological scoring for steatosis, cellular hypertrophy, 
and necroinflammation was performed on hematoxylin/eosin 
(H/E)-stained sections of the median liver lobe as described pre-
viously (44). H/E and Sirius Red staining was performed on 3 µm 
paraffin sections, whereas for Oil Red O staining 5 µm cryosec-
tions were used. The sections were examined using an AxioCam 
HRc (Zeiss) on a Zeiss Axio Imager.Z2 microscope with AxioVi-
sion version 4.8.2 software.
Flow cytometry analysis
After the removal of the median and the left liver lobes for RNA 
isolation and histological and oxysterol extraction, the liver was per-
fused with 0.1% Collagenase IV (Sigma-Aldrich). The liver was then 
removed and minced, and intrahepatic mononuclear cells were pu-
rified using a Ficoll gradient. The LIVE/DEAD Fixable Dead Stain 
Kit (Life Technologies) was used for the exclusion of dead cells. 
Data acquisition was performed on a FACSCanto II (BD Biosciences), 
and FlowJo (FlowJo LLC) software was used for data analysis.
Statistics
Unless otherwise indicated, data are presented as means ± 
SEMs. Statistical analysis was performed using GraphPad Prism 
(GraphPad Software). Significance was assessed using the Mann-
Whitney U test, with P < 0.05 considered statistically significant.
RESULTS
Liver oxysterol levels in patients with NASH
We acquired liver biopsies from 13 patients during bar-
iatric surgery and control liver samples without peripheral 
liver pathology findings from 4 patients undergoing partial 
liver resection. Histopathological analysis revealed NASH 
in nine bariatric patients and healthy liver tissue in four 
bariatric and the four remaining patients. NASH patients 
had a higher BMI and higher C-reactive protein, total cho-
lesterol, ApoA1, and ApoB compared with controls (Table 1, 
supplemental Table S1).
In comparing free oxysterol levels in bariatric patients 
with NASH with controls without NASH, we found higher 
levels of 7-HC, 7-HCO, 7,27-diHCO, and 7,12-diHCO 
(Scheme 1A, Fig. 1). Further, levels of 24S-HC, 24R-HC, 
and 7-HC were increased in NASH. In contrast, concentra-
tions of 25-HC and 27-HC did not differ between individu-
als with and without liver inflammation. Levels of 7-HC, 
7-HCO, 7,27-diHC, 24S-HC, 24R-HC, and 7-HC strongly 
correlated with disease activity, as assessed by the quantifi-
cation of liver inflammation using the NAFLD activity score 
(NAS) (Table 2), confirming the possible association of 
increased oxysterols with NASH.
Levels of liver free cholesterol were slightly higher in 
NASH livers but not significantly different from the control 
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(supplemental Fig. S1), suggesting that increased levels of 
free oxysterols are not simply due to the general effects of 
NASH on sterol composition. In fact, when oxysterol levels 
were normalized to cholesterol concentration, all significant 
differences for oxysterols remained in place, even though 
with slightly lower significance (supplemental Fig. S2).
A murine long-term feeding model of NASH with 
increased body weight, liver steatosis, and inflammation
To study the role of oxysterols in NAFLD/NASH in more 
detail, we established a murine feeding model in C57BL/6 
mice. Eight-week-old male mice were fed for 20 weeks with 
a high-fat, high-cholesterol diet (75% fat, 14% carbohydrates, 
11% proteins, 1.25% w/w cholesterol) and high-fructose 
corn-syrup equivalent (55% fructose and 45% glucose) in 
the drinking water (42) (HFD) or with standard chow and 
normal drinking water as the control (STD). We observed 
a steady increase in body weight (Fig. 2A), resulting in a 
significantly higher weight in HFD mice at the end of the 
experiment (HFD: 40.7 ± 6.2 g; STD: 35.2 ± 2.8 g; P = 0.01). 
Epididymal fat of HFD mice was also increased, indicating 
changes in fat distribution upon long-term HFD feeding 
(Fig. 2B). Macroscopically, livers were enlarged and pale 
(for representative images compare Fig. 2C). Histological 
analysis of H/E-stained liver sections of HFD mice revealed 
steatosis in 31 of 32 (97%; white arrow in Fig. 2D, left 
panel), cellular hypertrophy in 26 of 32 (81%; black ar-
row), and necroinflammation in 15 of 32 (47%; magnified 
in the inset). Steatosis was also apparent with Oil Red O 
staining, which showed a pronounced accumulation of fat 
droplets in HFD mice (Fig. 2D, right panel). Scores for ste-
atosis, cellular hypertrophy, and necroinflammation were 
assigned according to a general NAFLD scoring system for 
rodent models (44), which is an adaption of the classifica-
tion of Kleiner et al. (45). NASH is histologically defined as 
the combination of each of the following three key ele-
ments: i) steatosis, ii) cellular hypertrophy or ballooning, 
and iii) the presence of necroinflammation. Overall, 15 of 
32 (47%) C57BL/6 mice developed NASH (Fig. 3, Table 3).
Normal liver histology was observed for all control mice 
without evidence of steatosis, hypertrophy, or necroinflam-
mation, resulting in a NAS of 0 for all mice tested (Fig. 3A, B).
TABLE 1. Characteristics of patients with NASH and controls
Variable NASH (n = 9) Controla (n = 8) P
Females [n (%)] 5 (55) 7 (87) 0.294
Age at sample, years [median (IQR)] 35.1 (28.2–38.3) 47.2 (36.6–56.6) 0.059
BMI, kg/m2 [median (IQR)] 45.4 (44.3–48.8) 31.2 (21.1–36.9) 0.0003
AST,b U/l [median (IQR)] 28 (25–49) 29 (21–36) 0.299
ALT,b U/l [median (IQR)] 35 (27–65) 21.5 (16.2–34.2) 0.102
NAS [n (%)]
 0 0 (0) 8 (100)
 1 0 (0) 0 (0)
 2 0 (0) 0 (0)
 3 3 (33.3) 0 (0)
 4 3 (33.3) 0 (0)
 5 3 (33.3) 0 (0)
Fibrosis 5 (55.5) 0 (0)
Statistical comparisons were carried out with the use of the Mann-Whitney U test and Fisher’s exact test.
a The control group includes four bariatric patients undergoing liver biopsy during surgery without NASH and 
without liver steatosis and patients undergoing partial liver resection due to liver metastasis of (one each) pancreatic 
carcinoma, rectum carcinoma, and gall bladder carcinoma as well as Ecchinococcus.
b Normal: <35 females and <50 males.
Scheme 1. Chemical structure and synthesis of oxysterols. Red arrows indicate higher levels found in NASH patients compared with con-
trols without NASH.
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Fibrosis, evaluated on Sirius Red-stained sections and 
quantified according to Kleiner et al. (45), was present in 6 
of 32 mice (19%) with a grade of 1-1a; only 2 mice (6%) 
developed a higher degree of fibrosis (Fig. 2D, middle 
panel; Fig. 3C; supplemental Table S2).
Liver damage in HFD mice was confirmed by signifi-
cantly elevated AST and ALT serum levels compared with 
the STD group (Fig. 2E). These changes were accompa-
nied by enhanced expression of Tnf mRNAs in liver tissue 
(Fig. 2F), pointing to ongoing liver inflammation. Taken 
together, all histological, biochemical, and immunological 
hallmarks for NASH were present in approximately 50% of 
the mice fed a long-term HFD in this study, confirming this 
model as a valid physiological murine model for the devel-
opment of NAFLD and NASH.
EBI2, CH25H, and CYP7B1 are not essential for HFD-
induced NASH
To clarify the role of the EBI2-7,25-diHC system in he-
patic inflammation, we analyzed H/E-stained liver sections 
of HFD-fed knockout mice of key players of oxysterol pro-
duction and signaling (Ebi2/, Ch25h/, and Cyp7b1/) 
and their respective wild-type littermate controls. Histologi-
cal hallmarks of NASH (steatosis, cellular hypertrophy, and 
necroinflammation) were detected in most mice after 20 
weeks of HFD feeding; however, no differences were noted 
when knockout mice (Ebi2/, Ch25h/, and Cyp7b1/) 
and their respective littermate wild-type controls were com-
pared (Fig. 3A, B). Fibrosis was also indistinguishable be-
tween wild-type and knockout mice (Fig. 3C). As expected, 
no liver pathology was observed in any of these knockout 
mice upon STD feeding.
Liver inflammation was confirmed by elevated serologi-
cal markers for liver inflammation, including AST and 
ALT upon HFD feeding, but no effects of EBI2, CH25H, 
and CYP7B1 knockouts were detected (Fig. 4). In line with 
these observations, the liver tissue mRNA expression level 
of Tnf as a marker for inflammation was increased upon 
HFD feeding, but no genotype-related differences were 
detected (Fig. 5).
Fig. 1. Liver oxysterol levels in patients with NASH versus controls. Levels of various oxysterols were determined in human liver samples 
from nine patients with NASH (black squares: with fibrosis; white squares: no fibrosis) and eight controls. Statistical analysis: Mann-Whitney 
U test. ***P < 0.001, **P < 0.01, and *P < 0.05.
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Additionally, mRNA analysis of the key players of the 
EBI2-7,25-diHC system in wild-type mice revealed signifi-
cant increases of Ebi2 and Ch25h levels and a significant 
downregulation of Cyp7b1 upon HFD feeding when pooling 
all wild-type mice of the three independent experiments 
(supplemental Fig. S3). However, when the different knock-
out mice were compared with their respective wild-type 
littermate controls, the differences in Ebi2 and Cyp7b1 ex-
pression were not significant. Surprisingly, expression lev-
els of Ch25h were decreased in Ebi2/ knockout mice 
compared with wild-type littermate controls for STD as well 
as after HFD feeding (Fig. 5).
To test for the effects of Ebi2, Ch25h, and Cyp7b1 at an 
initial stage in NASH pathogenesis a different time point 
was tested. After 10 weeks of HFD feeding most mice devel-
oped steatosis (33 of 34; 97%) and cellular hypertrophy 
(28 of 34; 83.2%), but no necroinflammation was detect-
able at this time point (supplemental Fig. S4). Similar to 
the results for the 20-week HFD feeding, steatosis and cel-
lular hypertrophy scores were indistinguishable between 
the wild-type and knockout mice with a deficiency in the 
EBI2-7,25-diHC system.
Recruitment of immune cells into the inflamed liver  
did not differ in mice with a deficient EBI2-7,25- 
diHC system
Intrahepatic mononuclear cells were isolated from livers 
after 20-week HFD or STD feeding, and flow cytometry 
analysis was performed to test for the differential recruit-
ment of immune cells in mice with a dysfunctional EBI2-
7,25-diHC system. However, no differences were detected 
in major immune cell populations, including B-cells, CD4+ 
T-helper cells, and CD8+ cytotoxic T-cells (supplemental 
Fig. S5). Only very low numbers of dendritic cells and mac-
rophages were present in the liver of STD- and HFD-fed 
mice, making quantification inappropriate.
Increased liver oxysterol and cholesterol levels upon  
HFD feeding
Free oxysterols and cholesterol measurements by LC-
MS in mouse livers revealed elevated levels for some 
oxysterols in HFD-fed C57BL/6 mice (Fig. 6, supplemen-
tal Table S3).
Similar to humans, levels of 7-HCO were significantly 
elevated upon HFD feeding. However, the difference was 
smaller compared with human samples, and HFD feeding 
did not alter 7,27-diHCO and 7,12-diHCO levels. As 
in humans, 24-hydroxylated oxysterols (24S-HC, 24R-HC) 
were significantly increased upon HFD feeding. In addi-
tion, 22R-HC, 20R,22R-diHC, and 20R,22R-diHCO, which 
were not detectable in human livers, were also significantly 
increased (supplemental Fig. S6). HFD feeding also signifi-
cantly increased cholesterol levels (supplemental Fig. S6A). 
After normalizing for liver cholesterol levels, the difference 
in 7-HCO concentrations was no longer significant (sup-
plemental Fig. S7).
DISCUSSION
In this study, we performed a detailed analysis regarding 
the role of oxysterols and the oxysterol-EBI2 axis in NASH 
using human samples and murine samples from a feeding 
model of NASH. We demonstrated a NAFLD/NASH- 
dependent increase in free oxysterols in human livers and 
in mice. Detailed experiments in a murine feeding model 
of NASH demonstrated an upregulation of Ebi2 and Ch25h 
and a downregulation of Cyp7b1 (supplemental Fig. S3). 
However, knockouts of EBI2 and the oxysterol-producing 
enzymes Ch25h and Cyp7b1 did not show significant differ-
ences in NAFLD disease activity, excluding an essential role 
of these genes, at least in this murine model of NASH.
The level of 7-HCO is normally regarded as a marker 
for bile acid synthesis. It has been reported that the serum 
level of 7-HCO is significantly increased in patients with 
NASH (46–48). In another study, it was shown that the 
mRNA expression of CYP7A1, the rate-limiting enzyme 
in bile acid synthesis, was induced in human NASH livers 
(49). In partial agreement with a previous study (48), we 
found that the level of 7-HC and its downstream metabo-
lites 7-HCO, 7,12-diHCO, and 7,27-diHCO were sig-
nificantly higher in NASH livers, which directly confirmed 
TABLE 2. Correlation of oxysterol levels with NASH disease activity
Measured 
Oxysterol  
(pg/mg liver)
Humans Mice
Control (n = 8)  
[median (min  max)]
NASH (n = 9)  
[median (min  max)]
Correlation with  
NAS: r, p
STD (n = 8)  
[median (min  max)]
HFD (n = 10)  
[median (min  max)]
Correlation with 
NAS: r, p
7-HCO 14.82 (2.69–108.79) 457.20 (271.19–1006.33) 0.744, 0.0006 238.36 (59.67–1709.92) 709.85 (245.31–1709.92) 0.184, 0.4651
7,27-diHCO 4.20 (1.67–16.46) 21.29 (9.27–81.52) 0.685, 0.0024 60.26 (30.18–106.49) 49.57 (29.12–106.49) 0.212, 0.3983
7,12-diHCO 0 (0–1.90) 2.97 (0–9.24) 0.474, 0.0545 9.24 (2.12–22.41) 7.70 (2.77–22.41) 0.280, 0.2602
7-HC 10.93 (5.00–57.66) 129.93 (68.23–276.22) 0.877, <0.0001 87.01 (18.37–552.89) 76.34 (0–552.89) 0.268, 0.2815
7,27-diHC 3.06 (0.15-–34.80) 5.48 (1.33–16.10) 0.098, 0.7087 1.91 (0–32.81) 5.16 (0–32.81) 0.019, 0.9414
7,12-diHC 0 (0–0.62) 0.28 (0–14.07) 0.373, 0.1404 0 (0–2.90) 0.33 (0–2.90) 0.500, 0.0345
7-HC 14.10 (0–35.64) 54.15 (20.11–167.52) 0.756, 0.0004 84.03 (47.88–1099.57) 314.98 (100.54–1099.57) 0.493, 0.0375
6-HC 4.20 (0–33.47) 11.38 (6.00–17.67) 0.475, 0.0542 14.99 (4.45–481.55) 72.26 (29.28–481.55) 0.184, 0.4651
24S-HC 16.6 (12.3–57.2) 58.32 (34.85–122.83) 0.757, 0.0004 3.67 (1.05–18.87) 12.43 (4.42–18.87) 0.713, 0.0009
24R-HC 5.06 (0–9.47) 10.89 (6.65–17.10) 0.779, 0.0002 15.35 (7.17–99.51) 64.44 (42.45–99.51) 0.817, <0.0001
25-HC 9.95 (5.39–17.56) 10.30 (4.21–21.58) 0.086, 0.7425 15.46 (4.00–61.19) 40.05 (13.00–61.19) 0.476, 0.0459
27-HC 288.92 (25.89–905.65) 202 (25.93–900.90) 0.053, 0.8384 83.03 (4.32–725.84) 226.40 (34.15–725.84) 0.329, 0.1827
Oxysterols levels (pg /mg liver tissue) of human and murine liver samples and correlations of the respective oxysterol concentration with 
histological disease activity (NAS) are indicated. Significant correlations are shown in bold. Spearman’s rank-order correlation was used for statistical 
analysis. 6-HC was derived from cholestan-3,5,6-triol during sample preparation.
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Fig. 2. Increased body weight and liver inflammation in mice fed an HFD for 20 weeks. A: Weight development in male HFD and STD 
C57BL/6 mice. B: Epididymal fat weight as a percentage of total body weight after 20-week HFD feeding in C57BL/6 mice. C: Macroscopic 
aspect of livers from STD and HFD C57BL/6 mice. D: Representative H/E (left), Sirius Red (middle), and Oil Red O staining (right) of STD 
(upper panel) and HFD (bottom panel) wild-type mice, illustrating steatosis (white arrow), necroinflammation (inserts with magnification), 
cellular hypertrophy (black arrow), fat accumulation (middle panel), and collagen deposition (right panel). Scale bar: 100 µm. E: Serum 
liver function tests (AST and ALT) in HFD and STD mice. F: Liver tissue was analyzed for mRNA expression of Tnf, normalized to Hprt. 
Statistical analysis: Mann-Whitney U test, n  9. ***P < 0.001, **P < 0.01, and *P < 0.05.
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Fig. 3. EBI2, CH25H, and CYP7B1 are not essential for the induction of NASH by HFD. A: Quantification of liver inflammation by the NAS 
of Ebi2/ (upper panel), Ch25h/ (middle panel), and Cyp7b1/ (bottom panel). Each column represents one individual mouse. White frac-
tions of bars represent steatosis scoring (including both micro- and macrosteatosis), light blue fractions represent cellular hypertrophy, and 
dark blue fractions represent necroinflammation scoring. Quantification of (B) NAS and (C) fibrosis score in STD and HFD knockout mice 
and the respective littermate controls. Each dot represents one mouse, and wild-type mice are shown together with their respective littermate 
controls; wt vs. Ebi2/: n = 12 + 10, wt vs. Ch25h/: n = 11 + 11, and wt vs. Cyp7b1/: n = 9 + 15.
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the upregulation of bile acid synthesis associated with 
NASH. We also found an increase of 24S-HC and 24R-HC 
in humans and mice with NASH. 24S-HC is mainly pro-
duced in the brain by the enzyme cholesterol 24S-hydrox-
ylase (CYP46A1), which is expressed in neurons. After 
enzymatic conversion, 24S-HC is able to cross the blood-
brain barrier and is metabolized in the liver by the enzyme 
24-hydroxycholesterol 7--hydroxylase (CYP39A1) to 7,24S-
diHC and then to bile acids. To the best of our knowledge, 
the 24-HC epimers have, so far, not been implicated in 
NASH. The mechanism of 24-HC accumulation in NASH 
remains unclear; the most likely explanation for 24S-HC 
accumulation is decreased downstream metabolism. The 
origin of 24R-HC is not known, and it is seldom ana-
lyzed in MS studies. The level of 7,24S-diHC is below its 
detection limit (<5 pg/mg liver), but in future studies 
we will investigate whether CYP39A1 is downregulated in 
NASH livers.
TABLE 3. Histological scores of the HFD-fed knockout mice and the respective littermate controls
Wild-Type: Ebi2+/+  
(n = 12) 
Ebi2/  
(n = 10)
Wild-Type:  
Ch25h+/+ (n = 11)
Ch25h/  
(n = 11)
Wild-Type:  
Cyp7b1+/+ (n = 9)
Cyp7b1/  
(n = 15)-
Histological Feature Score/Code n (%)
Steatosis grade <1 1 (8) 0 0 0 0 0
1 to <2 6 (50) 2 (20) 6 (54.5) 6 (55) 1 (11) 1 (7)
2 to <3 4 (33) 7 (70) 5 (45.5) 5 (45) 6 (67) 11 (73)
3 1 (8) 1 (10) 0 0 2 (22) 3 (20)
Lobular inflammation 0 6 (42) 4 (40) 7 (63.6) 5 (45) 4 (44) 8 (53)
1 4 (33) 5 (50) 4 (36.4) 4 (36) 5 (56) 4 (27)
2 2 (25) 0 0 2 (18) 0 3 (20)
3 0 1 (10) 0 0 0 0
Cellular hypertrophy 0 3 (25) 2 (20) 3 (27.3) 4 (36) 0 1 (7)
1 5 (42) 3 (30) 4 (36.4) 5 (45) 9 (100) 11 (73)
2 2 (17) 4 (40) 2 (18.2) 2 (18) 0 3 (20)
3 2 (17) 1 (10) 2 (18.2) 0 0 0
Fibrosis stage 0 9 (75) 4 (40) 10 (90.9) 10 (91) 5 (56) 10 (67)
1-1a 1 (8) 4 (40) 1 (9.1) 1 (9) 4 (44) 3 (20)
1b 1 (8) 1 (10) 0 0 0 2 (13)
1c 0 0 0 0 0 0
2 1 (8) 1 (10) 0 0 0 0
Fig. 4. HFD increases liver function tests in mice in-
dependent of EBI2, CH25H, and CYP7B1 gene func-
tion. Quantification of serum AST and ALT in STD 
and HFD (A) Ebi2/, (B) Ch25h/, and (C) Cyp7b1/ 
mice and the respective littermate wild-type controls 
(nSTD = 2–8; nHFD  9). Statistical analysis: Mann-Whitney 
U test.
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In clinical practice, the diagnosis of NASH remains dif-
ficult, and reliable biomarkers are lacking. Liver biopsy is 
considered the gold standard for diagnosing NASH, which 
remains an invasive procedure and can both over- or un-
derestimate inflammatory activity due to sampling error. 
The pattern of increased levels of 7-HC, 7-HCO, 24S-HC, 
and 24R-HC suggest that they could be used as markers 
for NASH. Moreover, these oxysterols strongly and signifi-
cantly correlated with the severity of NASH according to 
the NAFLD disease severity score. A future study will check 
whether these changes are reflected in plasma. A panel of 
20 metabolites has been suggested for the distinction of 
NASH from steatosis in a previous lipidomics study (48).
NAFLD and NASH have been intensively studied in animal 
models (50). However, the validity of some animal models 
has been questioned: The use of a methionine- and choline-
deficient diet and/or genetic models, including mutations 
or knockout of key genes for the regulation of eating behav-
ior such as the leptin or leptin receptor gene, can rapidly 
induce liver inflammation, but these nonphysiological inter-
ventions result in the loss of important aspects of NAFLD 
pathogenesis (51, 52). For our study, we established a high-
fat, high-cholesterol, high-fructose diet murine feeding model 
of NAFLD, which spontaneously progresses to steatohepati-
tis. As a result, obesity with increased epididymal adiposity, 
increased AST and ALT serum levels, and upregulated 
liver expression of the inflammatory marker Tnf were in-
duced, reflecting features of the human disease. In our 
experiments, steatohepatitis developed in approximately 
50% of the mice in a time-dependent manner, and a low 
number of mice even progressed to pericellular fibrosis. 
Compared with other models the degree of liver injury was 
intermediate; this, together with the fact that steatohepatitis 
developed in only half of the mice, should be considered as 
a strength of our study because it allows an assessment of 
inhibition as well as stimulation of liver steatosis and inflam-
mation by additional interventions, such as the genetic 
knockout of Ebi2, Cyp7b1, or Ch25h. HFD feeding models 
such as ours with high caloric intake, rich in cholesterol, 
saturated fats, and fructose are time-consuming but ade-
quately reflect the human condition.
Several lines of evidence suggest a broad and general 
role of oxysterols in NASH pathogenesis (14, 15, 53, 54). 
However, here we show that loss of the enzymes CH25H 
and CYP7B1, and thus inhibition of 25-HC and 7,25-
diHC synthesis, did not show any significant differences in 
NASH activity compared with their wild-type littermate 
controls, arguing against an essential role of these two en-
zymes and their immediate products in NASH pathogen-
esis. However, cholesterol oxidation at position 25 is not 
Fig. 5. HFD changes the expression levels of genes involved in oxysterol metabolism and increases the expression of Tnf independent from 
EBI2, CH25H, and CYP7B1 gene function. Quantification of liver tissue mRNA level of Ebi2, Cyp7b1, Ch25h, and Tnf in STD and HFD (A) 
Ebi2/, (B) Ch25h/, and (C) Cyp7b1/ mice and the respective littermate wild-type controls (nSTD  5; nHFD  9). Statistical analysis: Mann-
Whitney U test. ***P < 0.001, **P < 0.01, and *P < 0.05.
1280 Journal of Lipid Research Volume 60, 2019
limited to CH25H, and the action of other enzymes, includ-
ing CYP27A1 and CYP3A4, can also lead to 25-HC (55). 
CYP3A11 in mice and CYP3A4 in humans can introduce a 
25-hydroxy group to 7-HC, providing an alternative route 
to 7,25-diHC via CYP7A1 and CYP3A4 in humans or 
CYP3A11 in mice (56). Therefore, our results do not com-
pletely exclude a role of 25-HC in NASH pathogenesis.
A previous study reported that the hematopoietic deple-
tion of CYP27A1 and thus the inhibition of 27-HC synthesis 
in another murine NASH model with knockout of low- 
density lipoprotein receptor (Ldlr/) and an HFD feeding 
for 12 weeks resulted in stronger NASH activity upon 
CYP27A1 depletion compared with wild-type controls. 
In line with these data, 27-HC applied subcutaneously sub-
stantially decreased liver inflammation (15). Furthermore, 
hematopoietic overexpression of CYP27A1 in the same 
mouse model was able to rescue the diet-induced liver in-
flammation (54). Due to differences of the animal models 
and the experimental approach, a direct comparison to our 
results is not possible. We stress the importance of using lit-
termate wild-type controls given the recognized crucial effect 
of the microbiota during the development of NAFL and 
NASH (57–61), which was rigorously done in all of our 
experiments. Further experiments will clarify whether 
27-HC [as suggested by Bieghs et al. (15)] is a critical player 
for the induction and progression of NASH.
24S, 25-HC, 27-HC and other side-chain oxysterols can 
retain sterol response element-binding proteins on the cy-
toplasmic surface of the endoplasmic reticulum and prevent 
their transcriptional activity (62). This results in reduced 
cholesterol synthesis and suppressive effects on the immune 
system (63). Additionally, side-chain oxysterols are agonists 
of the liver X receptors (LXRs) (55). The effects of LXR 
agonists on NASH are complex. On the one hand, LXR 
activation has broad anti-inflammatory effects (64, 65); on 
the other hand, LXR activation would increase endogenous 
Fig. 6. Liver oxysterol levels in a murine model of NAFLD/NASH. Eight-week-old male C57BL/6 mice were fed an HFD or STD for 20 
weeks. Levels of the indicated oxysterol in the liver tissue of HFD (black squares: NASH; white squares: NAFLD) and STD controls were 
measured by LC-MS. Statistical analysis: Mann-Whitney U test (nSTD = 8, 3 valid data points; nHFD = 10, 5 valid data points). ***P < 0.001, 
**P < 0.01, and *P < 0.05.
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lipogenesis, thus promoting liver steatosis (66). Due to this 
complexity, experiments in our study neither prove nor ex-
clude a general role of oxysterols through the LXR or 
SREBP pathway in NAFLD and NASH.
EBI2 was shown to be crucial for the migration of B-, T-, 
and dendritic cells (30, 31, 33, 67, 68). EBI2 was shown to 
mediate a fast antibody response (67) and was recently 
shown to play a significant role in the migration of T-cells 
in multiple sclerosis (35, 69), the migration of osteoclasts 
precursors in osteoporosis (70), and the activity of innate 
lymphoid cells in colitis (38). We report no effect of EBI2, 
CH25H, or CYP7B1 knockouts in the complex mechanisms 
of steatosis and inflammation during NASH pathogenesis, 
making essential effects of EBI2 or its ligand 7,25-diHC in 
NAFLD/NASH highly unlikely. Increased EBI2 enzyme 
levels in NASH livers (Fig. 5) might reflect an invasion of 
liver tissue with EBI2-expressing immune cells. However, 
only a minority of mice developed liver fibrosis. While no 
obvious effects on the limited number of animals with all 
knockout could be detected, further experiments in a liver 
fibrosis model might be warranted to show or exclude the 
effects of EBI2 on liver fibrosis.
An interesting observation in mice fed a HFD is the in-
creased abundance in the liver of the oxysterols 22R-HC 
and 20R,22R-diHC; these are the first two metabolites in 
the biosynthesis of steroid hormones from cholesterol in a 
reaction catalyzed by CYP11A1 (cholesterol side-chain 
cleavage enzyme), ultimately giving pregnenolone (71).
The clinical diagnosis of NASH remains a diagnostic 
challenge. The gold standard liver biopsy is an invasive pro-
cedure, and complications, including clinical significant 
bleeding, can occur. In addition, the degree of NASH could 
be over- or underestimated by liver biopsy due to sampling 
error (72). Thus, a noninvasive and reliable diagnostic tool 
for NASH is an unmet medical need, and future studies 
must clarify whether 24-HC in liver tissue or (preferably) 
plasma can be used as a diagnostic marker for NASH.
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